Floatz Rating
B58/100
Confidence
Indicative
Sponsor
University of Texas Southwestern Medical Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05249569CT.gov Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT04033991CT.gov Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. | — | Completed | — | — | — |
NCT03289533CT.gov A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) | — | Completed | — | — | — |
NCT02814461CT.gov The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC | — | Completed | — | — | — |
NCT01441388CT.gov A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. | — | Withdrawn | — | — | — |
NCT01352728CT.gov Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib | — | Completed | — | — | — |
NCT01273662CT.gov Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01334112CT.gov Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01210495CT.gov Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00447005CT.gov Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Axitinib (this asset) | University of Texas Southwestern Medical Center | P2 | B · 58 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Axitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Kidney Neoplasm | — | P3 | BB · 69 |
| Renal Cell Carcinoma | — | P4 | BB · 67 |
| Kidney Cancer | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Axitinib in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/axitinib-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →